Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Tech medical breakthrough

Dognosis AI Dog Cancer Breath Screening

Analysis based on 22 articles · First reported Sep 07, 2026 · Last updated Sep 12, 2026

Sentiment
15
Attention
2
Articles
22
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The development is a niche, early-stage healthcare technology story with no immediate listed-company exposure, so broad market impact is limited and mostly sentiment-driven for diagnostics and AI-healthcare themes. If the technology is validated and commercialized, it could pressure conventional cancer-screening providers while opening a low-cost diagnostics opportunity in emerging markets such as India.

healthcare biotechnology artificial intelligence

Bengaluru-based startup Dognosis is combining trained sniffer dogs with artificial intelligence to develop a non-invasive cancer screening test based on human breath samples. Dogs such as Chloe, a Labrador mix, wear 3D-printed helmets and harnesses fitted with sensors that record brain activity, respiration and body language while they sniff samples; AI then converts these reactions into quantitative data. Patients breathe into a cotton mask for about 10 minutes, and the sealed sample is analysed in the lab without the patient meeting the dogs. Dognosis says a study of more than 1,500 participants across six hospitals in Karnataka, published in the Journal of Clinical Oncology, achieved over 90 percent accuracy across seven major cancer types. Independent oncologists including Santhosh Kumar Devadas of M. S. Ramaiah Hospitals and Neelesh Reddy of Manipal Health Enterprises called the results promising but cautioned that much larger trials are needed before definitive conclusions. The company, backed by venture-capital firm Accel-KKR and co-founded by Akash Kulgod and Itamar Bitan, is collaborating with government medical institutions and hopes to launch commercially, reportedly in 2027, which it says would make it the third company of its kind after firms from Germany and Israel. India has described cancer as a major public health concern, with one in nine of its 1.4 billion people likely to develop the disease, making affordable early screening potentially significant.

70 Dognosis plans commercial launch
60 Dognosis collaborating with hospitals
55 Dognosis trained dogs
40 Accel-KKR backed startup Dognosis
30 Santhosh Kumar Devadas voiced cautious optimism Dognosis
25 Neelesh Reddy questioned technology usefulness Dognosis
priv
Central actor developing the AI-assisted canine cancer screening technology and reporting over 90 percent accuracy in its study. Commercial launch targeted for 2027, but independent validation is still pending.
Importance 100.0 Sentiment 30.0
per
Co-founder and CEO of Dognosis, the public face of the company's breath-based screening effort.
Importance 70.0 Sentiment 25.0
cnt
Home market where cancer is a major public health concern and where the low-cost screening approach could scale.
Importance 60.0 Sentiment 10.0
per
Co-founder who oversees dog training using positive reinforcement, drawing on his Israeli special-forces canine experience.
Importance 55.0 Sentiment 20.0
priv
Venture backer; positive news could increase value of its investment.
Importance 40.0 Sentiment 60.0
priv
Venture-capital backer of Dognosis, exposed to the startup's eventual commercial success or failure.
Importance 40.0 Sentiment 15.0
per
Oncologist who called the study promising as an early signal but urged much larger trials.
Importance 35.0 Sentiment 5.0
per
Oncologist who questioned how useful the technology will ultimately be for actual patients.
Importance 35.0 Sentiment 5.0
loc
State where study conducted; may gain healthcare innovation recognition.
Importance 30.0 Sentiment 40.0
priv
Partner hospital whose oncologist provided independent, cautiously optimistic commentary on the study.
Importance 30.0 Sentiment 5.0
priv
Partner hospital whose oncologist said only time will tell how useful the technology is for patients.
Importance 30.0 Sentiment 5.0
cnt
Referenced as home to one of the two existing companies of this kind, a competitive benchmark for Dognosis.
Importance 20.0 Sentiment 5.0
cnt
Referenced as home to one of the two existing companies of this kind, a competitive benchmark for Dognosis.
Importance 20.0 Sentiment 5.0
India related ↔ Accel-KKR
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.